Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Vabomere (Meropenem-Vaborbactam) In The Treatment Of Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT06672978 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) as lead sponsor.

NCT NCT06672978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06672978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Single-Arm, Phase 2 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Vabomere (Meropenem-Vaborbactam) In The Treatment Of Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 3, 2025
Completion date
July 31, 2027
Enrollment
66 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, complicated urinary tract infection